drugset
Drugs / Lilly Glucagon
last change Mar 2025 re-read 9 days ago

Lilly Glucagon

also known as glucagon · glucagon for injection (rDNA origin)
Developed for
hypoglycemia
Investigated by
Xeris Pharmaceuticals · Boston University · Emissary International LLC · Integrated Medical Development · Massachusetts General Hospital · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
+1 more · SGS S.A.

Trials 3

today NCT03439072 · Ph 3 NCT02701257 · not/applicable NCT01972152 · Ph 2
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT01972152 Oct 2013 → Feb 2014 hypoglycemia Xeris Pharmaceuticals Completed No outcome recorded
Phase 31 trial · 1 met primary
Phase 3 NCT03439072 Jan → Apr 2018 hypoglycemia, type 1 diabetes mellitus Xeris Pharmaceuticals Completed Met primary
Phase not applicable1 trial
— NCT02701257 Mar 2016 → May 2018 type 1 diabetes mellitus Massachusetts General Hospital Terminated No outcome recorded
Comparator or background therapy1 trial
Phase 1 NCT02403648 Comparator Nov 2014 → Mar 2015 hypoglycemia Biodel Completed No outcome recorded

Press releases naming this drug 23 releases

DateIssuerRelease
2025-03-17 Xeris Pharmaceuticals Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid xerispharma.com ↗
2021-04-29 Xeris Pharmaceuticals Xeris Pharmaceuticals Receives U.K. MHRA Approval of Ogluo® (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus xerispharma.com ↗
2021-02-12 Xeris Pharmaceuticals Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus xerispharma.com ↗
2020-12-11 Xeris Pharmaceuticals Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo™, Its Ready-To-Use (RTU) Glucagon for Injection, for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus xerispharma.com ↗
2020-06-15 Xeris Pharmaceuticals Xeris Pharmaceuticals Announces Positive Results From the Outpatient Stage of a Phase 2 Study of Its Developmental Gvoke Ready-to-Use (RTU) Micro™ Glucagon in Adults at Risk of Hypoglycemia During and After Aerobic Exercise xerispharma.com ↗
2020-05-22 Xeris Pharmaceuticals Xeris Pharmaceuticals Announces Positive Findings From the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery xerispharma.com ↗
2020-01-06 Xeris Pharmaceuticals Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise xerispharma.com ↗
2019-12-10 Xeris Pharmaceuticals Xeris Pharmaceuticals Announces Positive Topline Results From the In-clinic Stage of the Phase 2 Study of Its Developmental Ready-to-use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery xerispharma.com ↗
2019-09-10 Xeris Pharmaceuticals Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE™ (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia xerispharma.com ↗
2019-06-27 Xeris Pharmaceuticals Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery xerispharma.com ↗
2019-06-17 Xeris Pharmaceuticals Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon xerispharma.com ↗
2019-03-25 Xeris Pharmaceuticals Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon xerispharma.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Lilly Glucagon ClinicalTrials.gov intervention name — accepted as the source's own label NCT01972152 ↗
3

NCT03439072 ↗

NCT02403648 ↗

NCT02701257 ↗
Known as glucagon “glucagon” NCT02701257 ↗
Known as glucagon for injection (rDNA origin) “Lilly Glucagon(TM) \[glucagon for injection (rDNA origin)\], single 1 mg SC injection” NCT01972152 ↗
Route Subcutaneous “Lilly Glucagon(TM) \[glucagon for injection (rDNA origin)\], single 1 mg SC injection” NCT01972152 ↗